{"transactions":[{"id":708347,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-07-16T20:35:53.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":75,"price":82.62,"value":6196.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant."}],"balance_after":33992,"source":{"system":"sec-edgar","filing":"0001061983-26-000083","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000083/form4.xml","form_type":"4"}},{"id":762471,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2026-05-27T23:07:08.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":4301,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4301,"derivative":{"exercise_price":77.15,"exercise_date":"2026-06-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":4301},"source":{"system":"sec-edgar","filing":"0001061983-26-000054","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000054/form4.xml","form_type":"4"}},{"id":762470,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-27T23:07:08.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2851,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":33917,"source":{"system":"sec-edgar","filing":"0001061983-26-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000054/form4.xml","form_type":"4"}},{"id":808352,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-04-15T22:37:47.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":95,"price":65.37,"value":6210.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested."}],"balance_after":31066,"source":{"system":"sec-edgar","filing":"0001061983-26-000042","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000042/form4.xml","form_type":"4"}},{"id":937671,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-01-16T21:22:27.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":98,"price":63.44,"value":6217.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of our Board of Directors."}],"balance_after":30971,"source":{"system":"sec-edgar","filing":"0001061983-26-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000008/form4.xml","form_type":"4"}},{"id":1017799,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-10-16T20:32:35.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":99,"price":62.8,"value":6217.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Director equity in lieu of cash retainer program."}],"balance_after":30873,"source":{"system":"sec-edgar","filing":"0001061983-25-000010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198325000010/form4.xml","form_type":"4"}},{"id":1086855,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-07-16T21:45:34.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":164,"price":38.01,"value":6233.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Director equity in lieu of cash retainer program."}],"balance_after":30774,"source":{"system":"sec-edgar","filing":"0001127602-25-019292","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760225019292/form4.xml","form_type":"4"}},{"id":1149738,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2025-05-14T23:23:36.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":10880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors."}],"balance_after":10880,"derivative":{"exercise_price":30,"exercise_date":"2025-06-16","expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":10880},"source":{"system":"sec-edgar","filing":"0001127602-25-014354","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760225014354/form4.xml","form_type":"4"}},{"id":1149737,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-14T23:23:36.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Comprised of restricted stock units (\"RSUs\") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting."}],"balance_after":30610,"source":{"system":"sec-edgar","filing":"0001127602-25-014354","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760225014354/form4.xml","form_type":"4"}},{"id":1171206,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-04-16T20:02:43.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":162,"price":38.56,"value":6246.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to Director Stock in lieu of Cash Retainer Program."}],"balance_after":23277,"source":{"system":"sec-edgar","filing":"0001127602-25-012112","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760225012112/form4.xml","form_type":"4"}},{"id":1311567,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-01-06T21:23:40.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":127,"price":48.93,"value":6214.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Director Stock in Lieu of Cash Retainer Program"}],"balance_after":23115,"source":{"system":"sec-edgar","filing":"0001127602-25-000761","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760225000761/form4.xml","form_type":"4"}},{"id":1392515,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-03T21:24:18.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":118,"price":52.6,"value":6206.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock award in lieu of cash retainer payment."}],"balance_after":22988,"source":{"system":"sec-edgar","filing":"0001127602-24-025193","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760224025193/form4.xml","form_type":"4"}},{"id":1460776,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-07-04T00:07:47.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock award in lieu of cash retainer payment."}],"balance_after":22870,"source":{"system":"sec-edgar","filing":"0001127602-24-020150","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760224020150/form4.xml","form_type":"4"}},{"id":1514780,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2024-05-16T21:59:41.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":3636,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3636,"derivative":{"exercise_price":60.5,"exercise_date":"2024-06-17","expiration_date":"2034-05-15","underlying":"Common Stock","underlying_shares":3636},"source":{"system":"sec-edgar","filing":"0001127602-24-015718","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760224015718/form4.xml","form_type":"4"}},{"id":1514779,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-16T21:59:41.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22756,"source":{"system":"sec-edgar","filing":"0001127602-24-015718","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760224015718/form4.xml","form_type":"4"}},{"id":1693926,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-03T21:29:04.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":74,"price":84.12,"value":6224.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $84.12, representing the Issuer's closing stock price on January 2, 2024."}],"balance_after":17156,"source":{"system":"sec-edgar","filing":"0001127602-24-000441","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760224000441/form4.xml","form_type":"4"}},{"id":1768485,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-03T20:13:41.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":224,"price":27.88,"value":6245.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.  Shares are full vested from the moment of grant.  Shares issued at per share price of $27.88, representing the Issuer's closing stock price on October 2, 2023."}],"balance_after":17082,"source":{"system":"sec-edgar","filing":"0001127602-23-025160","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760223025160/form4.xml","form_type":"4"}},{"id":1832179,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2023-07-11T00:39:26.000Z","date":"2023-07-07","kind":"exercise","planned":false,"acquired":false,"shares":5957,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award is fully vested in accordance with its terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award is fully vested in accordance with its terms."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5957},"source":{"system":"sec-edgar","filing":"0001127602-23-020553","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760223020553/form4.xml","form_type":"4"}},{"id":1832178,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2023-07-11T00:39:26.000Z","date":"2023-07-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":1430,"price":29.88,"value":42728.4,"ownership":{"direct":true},"balance_after":20356,"source":{"system":"sec-edgar","filing":"0001127602-23-020553","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760223020553/form4.xml","form_type":"4"}},{"id":1832177,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2023-07-11T00:39:26.000Z","date":"2023-07-07","kind":"exercise","planned":false,"acquired":true,"shares":5957,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."}],"balance_after":21786,"source":{"system":"sec-edgar","filing":"0001127602-23-020553","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760223020553/form4.xml","form_type":"4"}},{"id":1837391,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-07-05T20:26:12.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":187,"price":33.36,"value":6238.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.  Shares are full vested from the moment of grant.  Shares issued at per share price of $33.36, representing the Issuer's closing stock price on July 3, 2023."}],"balance_after":16858,"source":{"system":"sec-edgar","filing":"0001127602-23-020071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760223020071/form4.xml","form_type":"4"}},{"id":1840966,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2023-06-30T20:38:28.000Z","date":"2023-06-29","kind":"grant","planned":false,"acquired":true,"shares":5985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 6/29/2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 6/29/2024."}],"balance_after":5985,"derivative":{"exercise_date":"2024-06-29","underlying":"Ordinary Shares","underlying_shares":5985},"source":{"system":"sec-edgar","filing":"0001127602-23-019636","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760223019636/form4.xml","form_type":"4"}},{"id":1840965,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2023-06-30T20:38:28.000Z","date":"2023-06-29","kind":"grant","planned":false,"acquired":true,"shares":12732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the stock option award vest and become exercisable in full on 6/29/2024."}],"balance_after":12732,"derivative":{"exercise_price":31.33,"exercise_date":"2024-06-29","expiration_date":"2033-06-29","underlying":"Ordinary Shares","underlying_shares":12732},"source":{"system":"sec-edgar","filing":"0001127602-23-019636","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760223019636/form4.xml","form_type":"4"}},{"id":1887368,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2023-05-18T21:08:52.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2023 and the last such installment vesting on 05/10/2024."}],"balance_after":10000,"derivative":{"exercise_price":37.89,"exercise_date":"2023-06-10","expiration_date":"2033-05-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001127602-23-016183","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760223016183/form4.xml","form_type":"4"}},{"id":1887367,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-18T21:08:52.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Comprised of restricted stock units that will vest in full and in one installment on 05/10/2024."}],"balance_after":16671,"source":{"system":"sec-edgar","filing":"0001127602-23-016183","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760223016183/form4.xml","form_type":"4"}},{"id":1897999,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2023-05-10T20:34:10.000Z","date":"2023-05-09","kind":"exercise","planned":true,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and sale of options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2023.  These options were scheduled to expire on May 15, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested in accordance with their terms."}],"balance_after":0,"derivative":{"exercise_price":31.13,"expiration_date":"2023-05-15","underlying":"Ordinary Shares","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001127602-23-015117","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760223015117/form4.xml","form_type":"4"}},{"id":1897998,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2023-05-10T20:34:10.000Z","date":"2023-05-09","kind":"exercise","planned":true,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and sale of options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2023.  These options were scheduled to expire on May 15, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested in accordance with their terms."}],"balance_after":0,"derivative":{"exercise_price":31.13,"expiration_date":"2023-05-15","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001127602-23-015117","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760223015117/form4.xml","form_type":"4"}},{"id":1897997,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2023-05-10T20:34:10.000Z","date":"2023-05-09","kind":"sale","planned":true,"acquired":false,"shares":41250,"price":31.2433,"value":1288786.125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and sale of options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2023.  These options were scheduled to expire on May 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.23 to $31.33. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request."}],"balance_after":15829,"source":{"system":"sec-edgar","filing":"0001127602-23-015117","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760223015117/form4.xml","form_type":"4"}},{"id":1897996,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2023-05-10T20:34:10.000Z","date":"2023-05-09","kind":"exercise","planned":true,"acquired":true,"shares":6250,"price":31.13,"value":194562.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and sale of options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2023.  These options were scheduled to expire on May 15, 2023."}],"balance_after":57079,"source":{"system":"sec-edgar","filing":"0001127602-23-015117","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760223015117/form4.xml","form_type":"4"}},{"id":1897995,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2023-05-10T20:34:10.000Z","date":"2023-05-09","kind":"exercise","planned":true,"acquired":true,"shares":35000,"price":31.13,"value":1089550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and sale of options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2023.  These options were scheduled to expire on May 15, 2023."}],"balance_after":50829,"source":{"system":"sec-edgar","filing":"0001127602-23-015117","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760223015117/form4.xml","form_type":"4"}},{"id":1912362,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:09:10.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.52,"underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001493152-23-013921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013921/ownership.xml","form_type":"4"}},{"id":1912361,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:09:10.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6.8,"underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001493152-23-013921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013921/ownership.xml","form_type":"4"}},{"id":1912360,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:09:10.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":12.62,"underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0001493152-23-013921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013921/ownership.xml","form_type":"4"}},{"id":1912359,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:09:10.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":128981,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":13.16,"underlying":"Common Stock","underlying_shares":128981},"source":{"system":"sec-edgar","filing":"0001493152-23-013921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013921/ownership.xml","form_type":"4"}},{"id":1925616,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-04-05T20:02:02.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":149,"price":37.71,"value":5618.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $37.71, representing the closing stock price of the Issuer's common stock on April 3, 2023."}],"balance_after":11671,"source":{"system":"sec-edgar","filing":"0001127602-23-012536","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760223012536/form4.xml","form_type":"4"}},{"id":2069392,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-01-04T23:42:46.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":126,"price":44.35,"value":5588.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.  Shares are full vested from the moment of grant.  Shares issued at per share price of $44.35, representing the Issuer's closing stock price on January 3, 2023."}],"balance_after":11522,"source":{"system":"sec-edgar","filing":"0001127602-23-000718","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760223000718/form4.xml","form_type":"4"}},{"id":2142691,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-05T20:25:14.000Z","date":"2022-10-03","kind":"grant","acquired":true,"shares":110,"price":51.11,"value":5622.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $51.11, representing the closing stock price of the Issuer's common stock on October 3, 2022."}],"balance_after":11396,"source":{"system":"sec-edgar","filing":"0001127602-22-023702","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760222023702/form4.xml","form_type":"4"}},{"id":2208739,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-07-12T20:41:46.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":137,"price":41,"value":5617.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $41.00, representing the closing stock price of the Issuer's common stock on July 1, 2022."}],"balance_after":11286,"source":{"system":"sec-edgar","filing":"0001127602-22-019243","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760222019243/form4.xml","form_type":"4"}},{"id":2209789,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2022-07-08T20:26:35.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":11554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the stock option award vest and become exercisable in full on 7/7/2023."}],"balance_after":11554,"derivative":{"exercise_price":31.48,"exercise_date":"2023-07-07","expiration_date":"2032-07-07","underlying":"Ordinary Shares","underlying_shares":11554},"source":{"system":"sec-edgar","filing":"0001127602-22-019136","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760222019136/form4.xml","form_type":"4"}},{"id":2209788,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2022-07-08T20:26:35.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":5957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the restricted stock unit award vest in full on 7/7/2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares subject to the restricted stock unit award vest in full on 7/7/2023."}],"balance_after":5957,"derivative":{"exercise_date":"2023-07-07","underlying":"Ordinary Shares","underlying_shares":5957},"source":{"system":"sec-edgar","filing":"0001127602-22-019136","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760222019136/form4.xml","form_type":"4"}},{"id":2229819,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2022-06-16T21:00:33.000Z","date":"2022-06-14","kind":"exercise","acquired":false,"shares":7585,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award is fully vested in accordance with its terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award is fully vested in accordance with its terms."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":7585},"source":{"system":"sec-edgar","filing":"0001127602-22-017641","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760222017641/form4.xml","form_type":"4"}},{"id":2229818,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2022-06-16T21:00:33.000Z","date":"2022-06-14","kind":"tax_withholding","acquired":false,"shares":695,"price":27.19,"value":18897.05,"ownership":{"direct":true},"balance_after":15829,"source":{"system":"sec-edgar","filing":"0001127602-22-017641","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760222017641/form4.xml","form_type":"4"}},{"id":2229817,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2022-06-16T21:00:33.000Z","date":"2022-06-14","kind":"exercise","acquired":true,"shares":7585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."}],"balance_after":16524,"source":{"system":"sec-edgar","filing":"0001127602-22-017641","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760222017641/form4.xml","form_type":"4"}},{"id":2265764,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-18T18:08:17.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 17, 2023."}],"balance_after":33000,"derivative":{"exercise_price":4.52,"expiration_date":"2032-05-17","underlying":"Common Stock, par value $0.0001","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001493152-22-014373","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315222014373/ownership.xml","form_type":"4"}},{"id":2275155,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-05-11T22:07:20.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2022 and the last such installment vesting on 05/10/2023."}],"balance_after":10000,"derivative":{"exercise_price":37.89,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001061983-22-000123","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198322000123/edgardoc.xml","form_type":"4"}},{"id":2275154,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-11T22:07:20.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Comprised of restricted stock units that will vest in full and in one installment on 05/10/2023."}],"balance_after":11149,"source":{"system":"sec-edgar","filing":"0001061983-22-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198322000123/edgardoc.xml","form_type":"4"}},{"id":2311677,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T23:17:59.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":146,"price":38.38,"value":5603.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $38.38, representing the Issuer's closing stock price on April 1, 2022."}],"balance_after":6149,"source":{"system":"sec-edgar","filing":"0001061983-22-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198322000091/edgardoc.xml","form_type":"4"}},{"id":2450729,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T21:48:27.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":122,"price":46,"value":5612.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $46.00, representing the Issuer's closing stock price on January 3, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 1,003 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program."}],"balance_after":6003,"source":{"system":"sec-edgar","filing":"0001061983-22-000014","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198322000014/edgardoc.xml","form_type":"4"}},{"id":2485441,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2021-12-04T02:29:27.000Z","date":"2021-12-02","kind":"exercise","acquired":false,"shares":5578,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award is fully vested in accordance with its terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award is fully vested in accordance with its terms."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5578},"source":{"system":"sec-edgar","filing":"0001127602-21-030305","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760221030305/form4.xml","form_type":"4"}},{"id":2485440,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2021-12-04T02:29:27.000Z","date":"2021-12-02","kind":"tax_withholding","acquired":false,"shares":1339,"price":22.11,"value":29605.29,"ownership":{"direct":true},"balance_after":8939,"source":{"system":"sec-edgar","filing":"0001127602-21-030305","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760221030305/form4.xml","form_type":"4"}},{"id":2485439,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2021-12-04T02:29:27.000Z","date":"2021-12-02","kind":"exercise","acquired":true,"shares":5578,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."}],"balance_after":10278,"source":{"system":"sec-edgar","filing":"0001127602-21-030305","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760221030305/form4.xml","form_type":"4"}},{"id":2552750,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-04T23:04:02.000Z","date":"2021-10-01","kind":"grant","acquired":true,"shares":153,"price":36.74,"value":5621.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.  Shares are full vested from the moment of grant.  Shares issued at per share price of $36.74, representing the Issuer's closing stock price on October 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 881 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program."}],"balance_after":5881,"source":{"system":"sec-edgar","filing":"0001061983-21-000233","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198321000233/edgardoc.xml","form_type":"4"}},{"id":2638673,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T21:32:24.000Z","date":"2021-07-07","kind":"grant","acquired":true,"shares":31,"price":19.77,"value":612.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.  Shares are full vested from the moment of grant.  Shares issued at per share price of $19.77, representing the Issuer's closing stock price on July 7, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 728 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program."}],"balance_after":5728,"source":{"system":"sec-edgar","filing":"0001061983-21-000192","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198321000192/edgardoc.xml","form_type":"4"}},{"id":2645670,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T22:01:47.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":238,"price":20.98,"value":4993.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.  Shares are full vested from the moment of grant.  Shares issued at per share price of $20.98, representing the Issuer's closing stock price on July 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 697 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program."}],"balance_after":5697,"source":{"system":"sec-edgar","filing":"0001061983-21-000176","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198321000176/edgardoc.xml","form_type":"4"}},{"id":2666016,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2021-06-16T20:30:52.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":7585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 6/14/2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 6/14/2022."}],"balance_after":7585,"derivative":{"exercise_date":"2022-06-14","underlying":"Ordinary Shares","underlying_shares":7585},"source":{"system":"sec-edgar","filing":"0001127602-21-020049","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760221020049/form4.xml","form_type":"4"}},{"id":2666015,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2021-06-16T20:30:52.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":15677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the stock option award vest and become exercisable in full on 6/14/2022."}],"balance_after":15677,"derivative":{"exercise_price":24.72,"exercise_date":"2022-06-14","expiration_date":"2031-06-14","underlying":"Ordinary Shares","underlying_shares":15677},"source":{"system":"sec-edgar","filing":"0001127602-21-020049","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760221020049/form4.xml","form_type":"4"}},{"id":2700653,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2021-05-21T20:41:41.000Z","date":"2021-05-20","kind":"exercise","acquired":false,"shares":6104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This restricted stock unit award vested in full on 5/20/2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This restricted stock unit award vested in full on 5/20/2021."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":6104},"source":{"system":"sec-edgar","filing":"0001127602-21-017792","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760221017792/form4.xml","form_type":"4"}},{"id":2700652,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2021-05-21T20:41:41.000Z","date":"2021-05-20","kind":"tax_withholding","acquired":false,"shares":1404,"price":21.92,"value":30775.68,"ownership":{"direct":true},"balance_after":4700,"source":{"system":"sec-edgar","filing":"0001127602-21-017792","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760221017792/form4.xml","form_type":"4"}},{"id":2700651,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2021-05-21T20:41:41.000Z","date":"2021-05-20","kind":"exercise","acquired":true,"shares":6104,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6104,"source":{"system":"sec-edgar","filing":"0001127602-21-017792","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760221017792/form4.xml","form_type":"4"}},{"id":2712417,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-14T19:57:53.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 12, 2022."}],"balance_after":23000,"derivative":{"exercise_price":6.8,"expiration_date":"2031-05-12","underlying":"Common Stock, par value $0.0001","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001493152-21-011599","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315221011599/ownership.xml","form_type":"4"}},{"id":2714997,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-05-14T00:04:44.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/12/2021 and the last such installment vesting on 05/12/2022."}],"balance_after":10000,"derivative":{"exercise_price":24.32,"exercise_date":"2021-06-12","expiration_date":"2031-05-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001061983-21-000146","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198321000146/edgardoc.xml","form_type":"4"}},{"id":2714996,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-14T00:04:44.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Comprised of restricted stock units that will vest in full and in one installment on 05/12/2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program."}],"balance_after":5459,"source":{"system":"sec-edgar","filing":"0001061983-21-000146","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198321000146/edgardoc.xml","form_type":"4"}},{"id":2758708,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T21:48:41.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":204,"price":24.44,"value":4985.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.  Shares are full vested from the moment of grant.  Shares issued at per share price of $24.44, representing the Issuer's closing stock price on April 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program."}],"balance_after":459,"source":{"system":"sec-edgar","filing":"0001061983-21-000101","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198321000101/edgardoc.xml","form_type":"4"}},{"id":2922131,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T23:19:17.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":255,"price":19.56,"value":4987.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.  Shares are full vested from the moment of grant.  Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 255 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program."}],"balance_after":255,"source":{"system":"sec-edgar","filing":"0001061983-21-000018","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198321000018/edgardoc.xml","form_type":"4"}},{"id":2956431,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2020-12-04T21:39:36.000Z","date":"2020-12-02","kind":"grant","acquired":true,"shares":5578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the restricted stock unit award vest in full on 12/2/2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares subject to the restricted stock unit award vest in full on 12/2/2021."}],"balance_after":5578,"derivative":{"exercise_price":0,"exercise_date":"2021-12-02","underlying":"Ordinary Shares","underlying_shares":5578},"source":{"system":"sec-edgar","filing":"0001127602-20-030583","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760220030583/form4.xml","form_type":"4"}},{"id":2956430,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2020-12-04T21:39:36.000Z","date":"2020-12-02","kind":"grant","acquired":true,"shares":11509,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable in full on 12/2/2021."}],"balance_after":11509,"derivative":{"exercise_price":18.82,"exercise_date":"2021-12-02","expiration_date":"2030-12-02","underlying":"Ordinary Shares","underlying_shares":11509},"source":{"system":"sec-edgar","filing":"0001127602-20-030583","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760220030583/form4.xml","form_type":"4"}},{"id":2971590,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-11-20T23:43:51.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":35000,"price":15.99,"value":559650.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable as to 35,000 shares divided into equal monthly installments with the first vesting installment on December 20, 2020 and the final vesting installment on November 20, 2023."}],"balance_after":35000,"derivative":{"exercise_price":15.99,"exercise_date":"2020-12-20","expiration_date":"2030-11-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001061983-20-000179","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198320000179/edgardoc.xml","form_type":"4"}},{"id":3081848,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-07-16T18:01:10.000Z","date":"2020-07-15","kind":"grant","acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"22,200 option shares vest on July 15, 2021."}],"balance_after":22200,"derivative":{"exercise_price":12.62,"expiration_date":"2030-07-15","underlying":"Common Stock, par value $0.0001","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0001493152-20-013475","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315220013475/ownership.xml","form_type":"4"}},{"id":3136947,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2020-05-22T20:26:10.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":6104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 5/20/2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 5/20/2021."}],"balance_after":6104,"derivative":{"exercise_price":0,"exercise_date":"2021-05-20","underlying":"Ordinary Shares","underlying_shares":6104},"source":{"system":"sec-edgar","filing":"0001127602-20-017779","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760220017779/form4.xml","form_type":"4"}},{"id":3136946,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2020-05-22T20:26:10.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":12823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option becomes exercisable in full on 5/20/2021."}],"balance_after":12823,"derivative":{"exercise_price":16.85,"exercise_date":"2021-05-20","expiration_date":"2030-05-20","underlying":"Ordinary Shares","underlying_shares":12823},"source":{"system":"sec-edgar","filing":"0001127602-20-017779","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760220017779/form4.xml","form_type":"4"}},{"id":3139270,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-21T16:06:45.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":128981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. The option vests in eight equal semi-annual installments commencing on November 19, 2020 and will become fully vested on May 19, 2024."}],"balance_after":128981,"derivative":{"exercise_price":13.16,"expiration_date":"2030-05-19","underlying":"Common Stock, par value $0.0001","underlying_shares":128981},"source":{"system":"sec-edgar","filing":"0001493152-20-009624","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315220009624/ownership.xml","form_type":"4"}},{"id":3248879,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2020-02-25T22:15:16.000Z","date":"2020-02-24","kind":"purchase","acquired":true,"shares":6940,"price":19.65,"value":136371.0,"ownership":{"direct":false,"nature":"The Nancy J. Wysenski Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 (\"The Nancy J. Wysenski Revocable Trust\")."}],"balance_after":11242,"source":{"system":"sec-edgar","filing":"0001127602-20-007701","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760220007701/form4.xml","form_type":"4"}},{"id":3374616,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-12T16:41:40.000Z","date":"2019-11-12","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option."}],"balance_after":0,"derivative":{"exercise_price":9.36,"expiration_date":"2029-04-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-056046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119056046/doc4.xml","form_type":"4"}},{"id":3374615,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-12T16:41:40.000Z","date":"2019-11-12","kind":"disposition_to_issuer","acquired":false,"shares":6274,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the \"Merger\") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which  represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the \"Merger\") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which  represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-056046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119056046/doc4.xml","form_type":"4"}},{"id":3493992,"issuer":{"id":147285,"kind":"organization","name":"TETRAPHASE PHARMACEUTICALS INC","symbol":"TTPH"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-11T23:22:07.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in equal quarterly installments over a one-year period measured from the date of grant."}],"balance_after":16500,"derivative":{"exercise_price":0.77,"expiration_date":"2029-06-09","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-19-036262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000120919119036262/doc4.xml","form_type":"4"}},{"id":3513244,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2019-05-23T22:39:28.000Z","date":"2019-05-22","kind":"grant","acquired":true,"shares":22400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable in full on 5/22/2020."}],"balance_after":22400,"derivative":{"exercise_price":25.04,"exercise_date":"2020-05-22","expiration_date":"2029-05-22","underlying":"Ordinary Shares","underlying_shares":22400},"source":{"system":"sec-edgar","filing":"0001127602-19-019718","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760219019718/form4.xml","form_type":"4"}},{"id":3545600,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-04-30T16:33:14.000Z","date":"2019-04-26","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, subject to continued service as a director though the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":9.36,"expiration_date":"2029-04-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-026571","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119026571/doc4.xml","form_type":"4"}},{"id":3590274,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2019-03-18T21:05:53.000Z","date":"2019-03-14","kind":"purchase","acquired":true,"shares":445,"price":33.06,"value":14711.7,"ownership":{"direct":false,"nature":"The Nancy J. Wysenski Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 (\"The Nancy J. Wysenski Revocable Trust\")."}],"balance_after":4302,"source":{"system":"sec-edgar","filing":"0001127602-19-011890","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760219011890/form4.xml","form_type":"4"}},{"id":3590273,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2019-03-18T21:05:53.000Z","date":"2019-02-21","kind":"purchase","acquired":true,"shares":3857,"price":33.09,"value":127628.13,"ownership":{"direct":false,"nature":"The Nancy J. Wysenski Revocable Trust"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Late filing due to administrative error."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 (\"The Nancy J. Wysenski Revocable Trust\")."}],"balance_after":3857,"source":{"system":"sec-edgar","filing":"0001127602-19-011890","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760219011890/form4.xml","form_type":"4"}},{"id":3670463,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-07T16:55:29.000Z","date":"2019-02-05","kind":"grant","acquired":true,"shares":6274,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests 50% on each of June 30, 2019 and 25% on each of September 30, 2019 and December 31, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer common stock."}],"balance_after":6274,"source":{"system":"sec-edgar","filing":"0001209191-19-008108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119008108/doc4.xml","form_type":"4"}},{"id":3883209,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-26T16:59:45.000Z","date":"2018-06-25","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third (1/3) of the total shares subject to the option shall vest on June 25, 2019 and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over two years, subject to the Reporting Person's continuous service through such vesting date"}],"balance_after":30000,"derivative":{"exercise_price":33.47,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-039514","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919118039514/doc4.xml","form_type":"4"}},{"id":3910528,"issuer":{"id":147285,"kind":"organization","name":"TETRAPHASE PHARMACEUTICALS INC","symbol":"TTPH"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-01T20:18:38.000Z","date":"2018-05-30","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in equal quarterly installments over a one-year period measured from the date of grant."}],"balance_after":12500,"derivative":{"exercise_price":3.68,"expiration_date":"2028-05-29","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-18-034670","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000120919118034670/doc4.xml","form_type":"4"}},{"id":3918452,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2018-05-24T22:29:39.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable in full on 5/23/19."}],"balance_after":17500,"derivative":{"exercise_price":45.64,"exercise_date":"2019-05-23","expiration_date":"2028-05-23","underlying":"Ordinary Shares","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001127602-18-018856","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760218018856/form4.xml","form_type":"4"}},{"id":4297902,"issuer":{"id":147285,"kind":"organization","name":"TETRAPHASE PHARMACEUTICALS INC","symbol":"TTPH"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-01T21:04:20.000Z","date":"2017-05-31","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in equal quarterly installments over a one-year period measured from the date of grant."}],"balance_after":12500,"derivative":{"exercise_price":6.89,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-17-036845","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000120919117036845/doc4.xml","form_type":"4"}},{"id":4304563,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2017-05-25T22:06:53.000Z","date":"2017-05-24","kind":"grant","acquired":true,"shares":14200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable in full on 5/24/18."}],"balance_after":14200,"derivative":{"exercise_price":58.25,"exercise_date":"2018-05-24","expiration_date":"2027-05-24","underlying":"Ordinary Shares","underlying_shares":14200},"source":{"system":"sec-edgar","filing":"0001127602-17-019451","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294596/000112760217019451/form4.xml","form_type":"4"}},{"id":490847,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2012-06-01T21:08:32.000Z","date":"2012-05-14","kind":"sale","acquired":false,"shares":372,"price":65,"value":24180.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan."}],"balance_after":32232,"source":{"system":"sec-edgar","filing":"0001209191-12-031713","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112031713/doc4a.xml","form_type":"4/A","original_submission_date":"2012-05-16"}},{"id":490846,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2012-06-01T21:08:32.000Z","date":"2012-05-14","kind":"sale","acquired":false,"shares":179628,"price":64.27,"value":11544691.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":32604,"source":{"system":"sec-edgar","filing":"0001209191-12-031713","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112031713/doc4a.xml","form_type":"4/A","original_submission_date":"2012-05-16"}},{"id":491215,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2012-05-16T20:33:31.000Z","date":"2012-05-14","kind":"exercise","acquired":false,"shares":3398,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":37383,"derivative":{"exercise_price":38.8,"exercise_date":"2011-05-03","expiration_date":"2021-02-02","underlying":"Common Stock","underlying_shares":3398},"source":{"system":"sec-edgar","filing":"0001209191-12-028591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112028591/doc4.xml","form_type":"4"}},{"id":491214,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2012-05-16T20:33:31.000Z","date":"2012-05-14","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":43750,"derivative":{"exercise_price":39.7,"exercise_date":"2010-03-09","expiration_date":"2019-12-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-12-028591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112028591/doc4.xml","form_type":"4"}},{"id":491213,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2012-05-16T20:33:31.000Z","date":"2012-05-14","kind":"exercise","acquired":false,"shares":147071,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":32929,"derivative":{"exercise_price":39.7,"exercise_date":"2010-03-09","expiration_date":"2019-12-08","underlying":"Common Stock","underlying_shares":147071},"source":{"system":"sec-edgar","filing":"0001209191-12-028591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112028591/doc4.xml","form_type":"4"}},{"id":491212,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2012-05-16T20:33:31.000Z","date":"2012-05-14","kind":"exercise","acquired":false,"shares":4531,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":67969,"derivative":{"exercise_price":37.86,"exercise_date":"2012-05-02","expiration_date":"2022-02-01","underlying":"Common Stock","underlying_shares":4531},"source":{"system":"sec-edgar","filing":"0001209191-12-028591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112028591/doc4.xml","form_type":"4"}},{"id":491211,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2012-05-16T20:33:31.000Z","date":"2012-05-14","kind":"sale","acquired":false,"shares":372,"price":65,"value":24180.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1."}],"balance_after":32232,"source":{"system":"sec-edgar","filing":"0001209191-12-028591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112028591/doc4.xml","form_type":"4"}},{"id":491210,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2012-05-16T20:33:31.000Z","date":"2012-05-14","kind":"sale","acquired":false,"shares":179628,"price":64.27,"value":11544691.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":32604,"source":{"system":"sec-edgar","filing":"0001209191-12-028591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112028591/doc4.xml","form_type":"4"}},{"id":491209,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2012-05-16T20:33:31.000Z","date":"2012-05-14","kind":"exercise","acquired":true,"shares":3398,"price":38.8,"value":131842.4,"ownership":{"direct":true},"balance_after":212232,"source":{"system":"sec-edgar","filing":"0001209191-12-028591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112028591/doc4.xml","form_type":"4"}},{"id":491208,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2012-05-16T20:33:31.000Z","date":"2012-05-14","kind":"exercise","acquired":true,"shares":25000,"price":39.7,"value":992500.0,"ownership":{"direct":true},"balance_after":208832,"source":{"system":"sec-edgar","filing":"0001209191-12-028591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112028591/doc4.xml","form_type":"4"}},{"id":491207,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2012-05-16T20:33:31.000Z","date":"2012-05-14","kind":"exercise","acquired":true,"shares":147071,"price":39.7,"value":5838718.7,"ownership":{"direct":true},"balance_after":183834,"source":{"system":"sec-edgar","filing":"0001209191-12-028591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112028591/doc4.xml","form_type":"4"}},{"id":491206,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2012-05-16T20:33:31.000Z","date":"2012-05-14","kind":"exercise","acquired":true,"shares":4531,"price":37.86,"value":171543.66,"ownership":{"direct":true},"balance_after":36763,"source":{"system":"sec-edgar","filing":"0001209191-12-028591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112028591/doc4.xml","form_type":"4"}},{"id":491549,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2012-05-09T20:40:07.000Z","date":"2012-05-08","kind":"exercise","acquired":false,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":68750,"derivative":{"exercise_price":39.7,"exercise_date":"2010-03-09","expiration_date":"2019-12-08","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001209191-12-027021","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112027021/doc4.xml","form_type":"4"}},{"id":491548,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2012-05-09T20:40:07.000Z","date":"2012-05-08","kind":"exercise","acquired":false,"shares":10196,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":40781,"derivative":{"exercise_price":38.8,"exercise_date":"2011-05-03","expiration_date":"2021-02-02","underlying":"Common Stock","underlying_shares":10196},"source":{"system":"sec-edgar","filing":"0001209191-12-027021","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112027021/doc4.xml","form_type":"4"}},{"id":491547,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16754,"kind":"person","name":"Wysenski Nancy","position":1,"cik":"0001294596","reported_name":"Wysenski Nancy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2012-05-09T20:40:07.000Z","date":"2012-05-08","kind":"exercise","acquired":false,"shares":9063,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20390,"derivative":{"exercise_price":33.82,"exercise_date":"2010-10-14","expiration_date":"2020-07-13","underlying":"Common Stock","underlying_shares":9063},"source":{"system":"sec-edgar","filing":"0001209191-12-027021","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112027021/doc4.xml","form_type":"4"}}],"next_cursor":"2012-05-09T20:40:07.000000Z,491547"}